Learn more about beta 2-microglobulin amyloidosis, a condition that may affect individuals who have been receiving long-term dialysis. The symptoms, incidence, and prevalence of this disease process as well as the differential diagnosis and treatment options are reviewed.
Continuing Education Instructions and Disclosure Information:
Contact hours available until 5/5/2023.
Requirements for Successful Completion: Complete the learning activity in its entirety and complete the online CNE evaluation. You will be able to print your CNE certificate at any time after you complete the evaluation.
Faculty, Planners, and Speakers Conflict of Interest Disclosure:
There are no other disclosures to declare.
Commercial Support and Sponsorship: No commercial support or sponsorship declared.
Accreditation Statement: American Nephrology Nurses Association (ANNA) is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
ANNA is an approved provider of continuing nursing education by the California Board of Registered Nursing, Provider Number CEP17499.
ANNA urges participants to be aware of the CNE requirements for relicensure in the states in which they hold a license.
Learning Outcome: Upon completion of this session the learner will describe the pathophysiology Beta 2 microglobin amyloidosis in the patient population receiving dialysis and implications for nursing care.